Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials

Autor:	Ignacio Matos, Cinta Hierro, Analia Azaro, Guillem Argiles, Maria Vieito, Rodrigo Dienstmann, Victor Rodriguez-Freixinos, Enriqueta Felip, Juan Martin-Liberal, Elena Garralda, Eva Muñoz-Couselo, Eudald Felip-Falg’s, Cristina Viaplana, Marinha Costa, Josep Tabernero, Mafalda Oliveira, Maria Ochoa de Olza, Gemma Mur-Bonet, Coral Perez-Gago, Irene Brana
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology Cancer Research medicine.medical_specialty business.industry Immune checkpoint inhibitors Incidence (epidemiology) Disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Medicine In patient Tumor growth business
Zdroj:	Journal of Clinical Oncology. 36:3032-3032
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.3032
Popis:	3032Background: HPD with ICIs has been recently described as progression disease (PD) by RECIST with a ≥ two-fold increase in tumor growth rate experimental vs. reference. However, the implementati...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::fe1b2276fa02d62f9e586f0f4a35aeac https://doi.org/10.1200/jco.2018.36.15_suppl.3032 Zobrazit plný text záznamu